|
The FDA seems oddly slow in oversight of unproven stem cell clinic-related firms like one here in California called Invitrx Therapeutics. I've written before about Invitrx, but interactions between them and the FDA have continued including a new warning letter. It's become a puzzling situation. More broadly, the FDA has done relatively little in the past two years on unproven stem …
|
|
